In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

Magazine

UTIPRO® PLUS Launched in Denmark

We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it is already present in Sweden, Norway and Finland, distributed as well by our partner RFSU.


Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.

Read more
Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October).

Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets.

TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.

TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL).

For more information about our products click here: http://noventure.com/products

Read more
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.

Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different etiologies in adults and children.

Read more

Let's meet in ...

2025, Oct 28

CPHI 2025